

2017 HFSA Comprehensive Review and Update: The Practical Management of Heart Failure

The 2017 Comprehensive Heart Failure Review Course builds upon the HFSA successful 2015 Review and 2016 Board Review Courses by incorporating results of new research studies, increasing focus on practical management recommendations, addressing issues encountered in practice, adding case studies, and providing breakout session in areas of special interest.

EDUCATIONAL FORMAT

Evidence-based presentations including guideline-based practice recommendations. Breakout sessions and case study sessions focusing on practical management issues

INTENDED AUDIENCE

Cardiologists, internists, nurses, clinical pharmacists and other health professionals with a special interest in heart failure.

LEARNING OBJECTIVES

At the conclusion of this educational activity, participants will be able to:

- Describe the epidemiology of heart failure and implement strategies for the prevention of heart failure.
- Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms.
- Assess and track the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
- Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents and non-pharmacologic options, such as diet and exercise; and implantable devices.
- Apply appropriate care strategies for patients with pulmonary hypertension, RV failure, heart failure with preserved ejection fraction, cardiorenal syndrome, peripartum and infiltrative myopathies.
- Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression.
- Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care.

- Describe characteristics of optimal candidates for cardiac transplantation or mechanical
- circulatory support.
- Apply strategies for atrial and ventricular arrhythmia management.
- Practice effectively in the context of health care reform and merit-based incentives.

CONTINUING EDUCATION CREDITS

The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Heart Failure Society of America designates this live activity for a maximum of **19.50 AMA PRA Category 1 Credits™**. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 19.50 MOC points in the Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This activity has been submitted to the Ohio Nurses Association for approval to award contact hours. The Ohio Nurses Association is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation (OBN-001-91).

Please call HFSA at 301-312-8635 for more information about contact hours.

Pharmacists: Please visit www.hfsa.org/hfreview for updated information regarding approved continuing education credit.

CONFLICT OF INTEREST

Jamie Abreu
(*Planning Committee*)
Nothing to disclose

Shauna Brown, MSL, PCMH CCE
(*Content Reviewer*)
Nothing to disclose

Cynthia Chauhan, MSW (Patient Representative)
Nothing to disclose

Sheryl L. Chow, PharmD, FHFSA

(Planning Committee & Presenter)

Speaker/Honoraria: Novartis

Consultant/Advisory Board: Novartis

Jennifer Cook, MD

Research Grant: Abbott, Acetilon, Amgen

Maria Rosa Costanzo, MD, FACC, FAHA

Employment: Advocate Medical Group

Research Grant: Abbott, Respicardia

Consultant/Advisory Board: Abbott, Medtronic, Boston Scientific, Respicardia, CHF-Solutions, Axon Technologies, Re-Think Medical, Paragate

Akshay Desai, MD, FHFSA

Research Grant: Novartis

Consultant/Advisory Board: Novartis, St. Jude/Abbott, AstraZeneca, Janssen, Relypsa, DalCor, Cheetah Medical

James C. Fang, MD, FHFSA

Consultant/Advisory Board: Actelion - SOPRANO Trial (DSMB), Caprico - ALLSTAR Trial (CEC), Amgen - Galactic HF Trial (Steering Committee), Novartis - EVALUATE HF Trial (Steering Committee), NIH - PVOMICS (OSMB), NIH - CTSN (Medical Monitor)

Gregg C. Fonarow, MD, FACC, FAHA, FHFSA

Speaker/Honoraria: Novartis

Research Grant: NIH

Consultant/Advisory Board: Novartis, Medtronic, Janssen, Amgen, ZS Pharma, St. Jude

Marie Galvao, MSN, ANP

(Planning Committee & Presenter)

Speaker/Honoraria: Merck

Consultant/Advisory Board: Boston Scientific

J. Thomas Heywood, MD

Research Grant: Abbott, Medtronic

Speaker/Honoraria: Abbott, Novartis

Consultant/Advisory Board: Abbott, Medtronic, Novartis

Ann Laramée, MS, ANP-BC, ACNS-BC, FHFSA

Employment: University of Vermont Medical Center

Dawn M. Lombardo, DO, MSc

Nothing to disclose

Alan S. Maisel, MD

Consultant/Advisory Board: Critical Dx

Research Grant: Novartis, Roche

Tien Ng, PharmD, FHFSA

Research Grant: Otsuka America Pharmaceuticals

Linda Ordway, NP
Nothing to disclose

Robert L. Page, II, PharmD, MSPH, FHFA
Nothing to disclose

J. Herbert Patterson, PharmD, FCCP, FHFA
Research Grant: Novartis, Amgen, Otsuka, Merck, Boehringer-Ingelheim
Consultant/Advisory Board: Novartis

Sean Pinney, MD
(Planning Committee & Presenter)
Consultant/Advisory Board: Abbott, CareDx
Speaker/Honoraria: CareDx

Lisa D. Rathman, MSN, CRNP
Consultant/Advisory Board: Medtronic, St. Jude, Stealth Biopharma
Research Grant: St. Jude
Speaker/Honoraria: St. Jude

Jonathan Rich, MD, FHFA
Speaker/Honoraria: Novartis
Consultant/Advisory Board: Medtronic

Nancy Sweitzer, MD, PhD
Nothing to disclose

Jeff Testani, MD
Research/Grant: FIRE1, Sanofi, Sequana Medical, Otsuka, Medtronic, Corvidia, Boehringer Ingelheim
Consultant/Advisory Board: FIRE1, Sanofi, Sequana medical, Cardionomic

Orly Vardeny, PharmD, FHFA
Research Grant: Novartis
Consultant/Advisory Board: Novartis